Company intelligence / Profile preview
GelMEDIX
Cambridge, Massachusetts, United Statesgelmedix.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
GelMEDIX’s lead program uses a hydrogel-based cell therapy designed to restore vision in patients with dry age-related macular degeneration (AMD) and geographic atrophy. Another advanced program focuses on a sustained-release corticosteroid subconjunctival implant for ocular inflammation. No published clinical results yet; programs are in preclinical or IND-enabling stages.
- Therapeutic areas
- OtherOphthalmology
- Modalities
- Small moleculesCell therapiesGene therapiesBiomaterials (hydrogel-based)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
HTL Biotechnology – equity investment and strategic support focused on biopolymer development and scale-up.
Beyond the preview
Go deeper on GelMEDIX.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GelMEDIX.